Brief: Chemomab Therapeutics Announces Collaboration With Leeds University To Further Elucidate Role Of CCL24 In Vascular Damage Associated With Systemic Sclerosis
27/09/2021 12:17
Sept 27 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS ANNOUNCES COLLABORATION WITH LEEDS
UNIVERSITY TO FURTHER ELUCIDATE ROLE OF CCL24 IN VASCULAR DAMAGE
ASSOCIATED WITH SYSTEMIC SCLEROSIS
Source text for Eikon: ID:nPn8HXC2ba
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update